A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents

Editorial

C Ritchlin et al. Ann Rheum Dis. 2006 Dec.

. 2006 Dec;65(12):1541-4.

doi: 10.1136/ard.2006.059261.

No abstract available

Conflict of interest statement

Competing interests: None declared.

See linked article, p 1680

Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists.
Carter JD. Carter JD. Ann Rheum Dis. 2006 Dec;65(12):1680. doi: 10.1136/ard.2006.054833. Ann Rheum Dis. 2006. PMID: 17105866 Free PMC article. No abstract available.

1. Efthimiou P, Markenson J A. Role of biological agents in immune‐mediated inflammatory diseases. South Med J 200598192–204. - PubMed
1. Ritchlin C. Newer therapeutic approaches: spondyloarthritis and uveitis. Rheum Dis Clin North Am 20063275–90. - PubMed
1. Bongartz T, Sutton A J, Sweeting M J, Buchan I, Matteson E L, Montori V. Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. J Am Med Assoc 20062952275–2285. - PubMed
1. Flendrie M, Vissers W H, Creemers M C, de Jong E M, van de Kerkhof P C, van Riel P L. Dermatological conditions during TNF‐alpha‐blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 20057666–676. - PMC - PubMed
1. Gaspari A A. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 200654(Suppl 2)S67–S80. - PubMed